PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia

B Yousefi; V Shafiei-Irannejad; A Azimi; N Samadi; N Zarghami

Issue

Vol. 62 No. 8: Issue 8

Issue Published : July 31, 2016

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia

B Yousefi

Tabriz University of Medical Sciences Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine Tabriz Iran

V Shafiei-Irannejad

Tabriz University of Medical Sciences Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine Tabriz Iran

A Azimi

Maragheh University of Medical Sciences Departmant of Basic Sciences Maragheh Iran

N Samadi

Tabriz University of Medical Sciences Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine Tabriz Iran

N Zarghami

Tabriz University of Medical Sciences Immunology Research Center Tabriz Iran

Corresponding Author(s) : B Yousefi

Cellular and Molecular Biology, Vol. 62 No VSports. 8: Issue 8 Article Published : July 31, 2016 .

Abstract

Peroxisome proliferator-activated receptor gamma (PPARÎ³) plays key roles in regulating cellular differentiation, proliferation and apoptosis pathways. As such, they are considered promising targets for anticancer drug development, especially for breast cancer, multiple myeloma and hematologic malignancies. Chronic myeloid leukemia (CML) is a myeloproliferative disorder arising from an oncogenic Bcr-Abl tyrosine kinase. Inhibitors of this oncogene by small molecules such as imatinib are effective only in 75% of the patient's population. One of the potential strategies to overcome this resistance is to devise combination therapy protocols with other therapeutic agents including PPAR ligands. Since PPAR ligands are potentially interesting in different hematologic malignancies, this article will review the potential of PPAR ligands for use in CML treatment.

Keywords

Chemotherapy CML Drug resistance imatinib PPARÎ³.

Yousefi, B., Shafiei-Irannejad, V., Azimi, A., Samadi, N., & Zarghami, N. (2016). PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia. Cellular and Molecular Biology, 62(8), 52–55. Retrieved from https://www.cellmolbiol.org/index.php/CMB/article/view/912